非霍奇金淋巴瘤 中国就医指南

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of malignant cancers originating from lymphoid tissue—primarily B lymphocytes (90% of cases), but also T cells or natural killer (NK) cells. Unlike Hodgkin lymphoma, NHL lacks the characteristic Reed-Sternberg cells and encompasses over 60 distinct subtypes, broadly classified as indolent (e.g., follicular lymphoma, marginal zone lymphoma), aggressive (e.g., diffuse large B-cell lymphoma—DLBCL, the most common subtype worldwide), and highly aggressive (e.g., Burkitt lymphoma). Pathogenesis involves cumulative genetic alterations—including chromosomal translocations (e.g., BCL2 in follicular lymphoma), mutations in epigenetic regulators (e.g., EZH2, CREBBP), immune evasion mechanisms, and chronic antigenic stimulation. Dysregulation of B-cell receptor signaling, NF-κB activation, and impaired tumor surveillance by T cells and NK cells further drive clonal expansion and survival of malignant lymphocytes. Epidemiologically, NHL incidence rises with age, with median diagnosis at 67 years; it accounts for ~4% of all cancers globally. In China, age-standardized incidence is approximately 5.2 per 100,000 persons annually, slightly lower than in North America or Western Europe but increasing steadily—likely due to aging populations, improved diagnostics, and environmental shifts. Key risk factors include immunosuppression (e.g., HIV infection, post-transplant immunosuppressive therapy), autoimmune disorders (e.g., Sjögren’s syndrome, rheumatoid arthritis), chronic infections (e.g., Epstein-Barr virus, Helicobacter pylori, HTLV-1), occupational exposures (e.g., pesticides, benzene), and family history of lymphoid malignancies. Notably, obesity and certain dietary patterns are emerging modifiable risks. Quality of life (QoL) impact is profound and multifaceted: patients frequently experience debilitating fatigue, night sweats, unexplained weight loss, recurrent fevers, and painless lymphadenopathy—symptoms that disrupt daily functioning, work capacity, and psychosocial well-being. Chemotherapy-induced cytopenias increase infection risk; immunotherapies may trigger immune-related adverse events (e.g., thyroiditis, pneumonitis); and long-term survivors face elevated risks of secondary malignancies, cardiovascular toxicity, and neurocognitive decline. Psychologically, anxiety about relapse, treatment uncertainty, and financial toxicity significantly impair mental health—studies report depression prevalence up to 35% among NHL patients undergoing active therapy. Supportive care integration—including palliative oncology, nutritional counseling, physical rehabilitation, and mental health services—is now recognized as essential to preserving functional status and patient-reported outcomes throughout the disease continuum.

# 非霍奇金淋巴瘤（NHL）治疗方案与费用明细（血液科）

一、非手术/保守/药物治疗方案

• •适用人群：初治低危B细胞型（如CLL/SLL、滤泡性淋巴瘤Ⅰ–Ⅱ期）、老年或合并症患者
• •方案明细：

- 药品费：¥38,000–¥62,000/周期（国产/进口利妥昔单抗价差显著） - 化疗药+支持用药：¥4,500–¥7,200/周期 - 必查项目（每周期）：血常规、肝肾功、LDH、CT/PET-CT（首疗程前必做）：¥2,800–¥8,500 - 靶向单药维持（如来那度胺、伊布替尼）：适用于复发/高龄患者 - 月均药费：¥12,000–¥28,000（医保谈判后降至¥3,200–¥9,800）

二、核心介入/根治性方案

• •适用人群：中高危弥漫大B细胞淋巴瘤（DLBCL）、原发纵隔B细胞淋巴瘤等需强化治疗者
• •方案明细：

- 全套费用：¥220,000–¥350,000（含CD34+细胞检测、无菌层流病房、粒缺期抗感染） - 术前检查（骨髓穿刺活检、心肺功能评估、病毒学筛查等）：¥6,500–¥9,800

三、特殊复杂/晚期/耐药方案

• •CAR-T细胞治疗（如泽布替尼联合CAR-T或二线CAR-T）：¥120万–¥138万元（含制备、桥接治疗、ICU监护）；PD-1抑制剂联合方案：¥8,000–¥15,000/月（限T细胞淋巴瘤特定亚型）

四、方案快速选择指南

• •预算≤5万：优选R-CHOP（国产药）+医保报销，覆盖约70%费用
• •预算15–30万+复发难治：推荐CAR-T桥接或auto-HSCT（三甲医院专项通道）
• •≥75岁/ECOG≥3：来那度胺±利妥昔单抗单药，年均支出¥3.8万–¥11.6万